AUTH/3161/2/19: Employee v Leo Pharma – briefing slides on call frequency breached Clause 15.9

📅 2019 | 🖉 Dr Anzal Qurbain
📊

Key facts

CaseAUTH/3161/2/19
PartiesEmployee v Leo Pharma
Complaint received19 February 2019
Case completed18 June 2019
Applicable Code year2016
AllegationsOver-frequent doctor visits; audits only for customers using Leo products; speaker slides not medically/legal approved; discouraging adverse event reporting; emailing customers without permission
Breach findingsClause 15.9
No breach findingsClauses 2, 9.1, 9.9, 14.1, 15.6, 19.1, 19.2
SanctionsUndertaking received; Additional sanctions: Not stated
AppealNo appeal
Core issue upheldInternal briefing slides referred to call frequencies of 4 and 5 without defining call vs contact or reiterating Code requirements, likely to lead to a breach

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • A named, non-contactable, current employee complained about Leo Pharma’s promotional practices.
  • Allegations included: encouraging representatives to visit doctors five times a year (more than 3 unsolicited visits), audits only for customers using Leo products, speaker slides not going through medical/legal approval, discouraging adverse event reporting, and emailing customers without permission.
  • The Panel noted the complaint provided only brief details and no supporting attachments/evidence.
  • On call frequency, the Panel focused on internal representative briefing material (topical dermatology customer segmentation plan slides) that referred to call frequencies of 4 and 5 but did not distinguish “calls” vs “contacts” or reiterate Code requirements.
⚖️

Outcome

  • Breach: Clause 15.9 (briefing material advocated a course of action likely to lead to a breach of the Code).
  • No breach: Clauses 2, 9.1, 9.9, 14.1, 15.6, 19.1, 19.2.
  • The Panel found no evidence that actual call numbers breached the Code; the issue was the clarity/content of the internal briefing slides.
  • Other allegations (audits, speaker slides approval, adverse event reporting, emailing without permission) were not proven on the balance of probabilities.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training